Background. Bordetella pertussis strains lacking expression of pertactin, a bacterial adhesin and vaccine target, are emerging. There are limited data on disease manifestations of mutant strains in children. We sought to compare clinical manifestations of pertactin-deficient and pertactin-producing B. pertussis infection in infants and describe corresponding molecular characteristics.
11-12-year-olds in 2005 resulted in a reduction in adolescent cases. The epidemiologic course of pertussis, however, changed again abruptly, as noted in the 2010 California epidemic, the 2012 Washington epidemic, and in national reporting. After infants, the highest case rates currently are observed in 7-10 and 13-14-year-olds, most often in fully vaccinated persons [2] . Considerable evidence suggests that early and progressive decline in protection after acellular pertussis vaccines-both pediatric diphtheria, tetanus toxoid, and acellular pertussis antigen vaccine (DTaP) and Tdap-is the major reason for the increase in cases [3] [4] [5] [6] , and that rapid reversion to susceptibility within a few years of vaccination has occurred in the cohort of vaccinees whose series consisted entirely of acellular vaccine [5, [7] [8] [9] .
Another possible contributing factor to increasing case rates is a change in Bordetella pertussis itself, which appears to have adapted under the selective pressure of vaccines. Pertactin protein is thought to play a role in B. pertussis microbial pathogenesis both as an adhesin in the bacterium-host cell interface and functionally in resistance to clearance by neutrophils [10, 11] . Most acellular pertussis vaccines, and all US vaccines, contain pertactin of allele type prn1. By the 1990s, vaccine-divergent pertactin type allele prn2 was the predominant circulating strain in the United States and most European countries [12] [13] [14] [15] . Since the 2000s, during the exclusive acellular pertussis vaccine era in many countries, B. pertussis strains deficient in pertactin have been noted to represent a small proportion of clinical isolates in Japan, France, Finland, Australia, and Canada [16] [17] [18] [19] [20] , and increased rapidly in Australia from 2008 to 2012 [19] . Pertactin-deficient B. pertussis was first described in the United States in 2013 by Queenan et al [21] , among isolates from infants cared for in our institution in 2011-2012. Recently resurgent pertussis in older children, adolescents and adults has been thought to be mild [6] , but there were 27 US deaths in 2010, almost exclusively in infants <2 months of age [22] . Reported clinical data on cases of pertactin-deficient B. pertussis are limited [1, 23] , generally including cases occurring during outbreaks and in previously immunized persons in whom pertussis is known to be less symptomatic [24, 25] . In addition, clinical data generally are from epidemiologically confirmed, rather than culture-confirmed, cases [7, 15] . It could be speculated that loss of a significant virulence factor in pertactin-deficient strains could lead to ameliorated disease manifestations or that loss of a major vaccine antibody target could facilitate prolonged disease.
The objectives of our study were to (1) investigate prevalence of pertactin-deficient B. pertussis strains among clinical isolates from predominantly young, unvaccinated infants with pertussis over a 7-year period in a single geographic area; (2) delineate antigen types, clonality, pertactin expression, and prn genetic mutations of isolates; and (3) determine whether clinical manifestations of cases due to pertactin-deficient and pertactinproducing strains B. pertussis differ.
METHODS
All cases of confirmed pertussis were retrospectively identified from January 2007 through March 2014 at a single tertiary care children's hospital in North Philadelphia that also serves a socioeconomically disadvantaged urban population. Cases were confirmed by culture, polymerase chain reaction (PCR), or direct fluorescent antibody testing. It has been standard practice at our institution to perform culture using Regan-Lowe agar on respiratory specimens collected from patients with suspected pertussis who are hospitalized or evaluated in the emergency department; clinical isolates routinely are frozen at −80°C. Although PCR testing for B. pertussis was introduced in September 2012, standard culturing was also continued. Only culture-positive cases with viable archived isolates were included for clinical characterization and molecular analysis. Archived isolates from before 2007 were not available.
Western blot analysis, pulsed-field gel electrophoresis (PFGE), PCR, and pertactin gene sequencing were performed on viable B. pertussis isolates. For molecular characterization, isolates were first analyzed for presence of pertactin by Western Blot. A 5-mL culture was grown overnight in Stainer-Scholte medium at 35°C. Cells were harvested by 200-rpm centrifugation and resuspended in saline before lysis with a FastPrep 24 homogenizer. Approximately 5 µg of protein lysate was run on 12% NuPAGE gels in MOPS buffer (Life Sciences). The proteins were transferred to polyvinylidene difluoride membranes with an iBlot apparatus, and pertactin was detected with National Institute for Biological Standards and Control anti-69K antiserum 97/558 at 1:1000 dilution, using the anti-goat Western Breeze Kit (Life Sciences). The pertactin-positive control was World Health Organization strain 18323.
PCR was performed using the AF, AR, BF, BR, PR8F, and PR8R primers from Mooi et al [26] The Platinum Blue PCR SuperMix (Invitrogen) was used with 10% dimethyl sulfoxide. Primers were used at 0.1 µmol/L concentration. Products were amplified using 95°C for 15 minutes, followed by 20 cycles of 94°C for 45 seconds, 55°C for 45 seconds, and 72°C for 2.5 minutes and 10 cycles of 94°C for 45 seconds, 50°C for 45 seconds, and 72°C for 2.5 minutes. PCR products were sequenced by ACGT.
PFGE was performed by digesting DNA in agarose plugs with restriction enzyme XbaI. DNA fragments were separated in 1% agarose gels in ×0.5 Tris-borate-ethylenediaminetetraacetic acid buffer at 5.5 V/cm for at 18°C for 16 hours, with a switch time of 5-6 seconds, and then 24 hours, with a switch time of 8-35 seconds. Gels were stained with SYBR Green, and DNA bands were visualized using UV light. PFGE types were assigned a letter and, where possible, matched to a published Centers for Disease Control and Prevention (CDC) profile number based on the characteristics of 11 pertactin-deficient isolates reported elsewhere [21] .
Medical records for all culture-confirmed cases were retrospectively reviewed to collect data for: demographics; clinical characteristics of disease presentation and severity; vaccine history; rates and duration of hospitalization, admission to an intensive care unit, and respiratory support; mortality rates; and laboratory test results. Data for cases caused by pertactin-deficient and pertactin-producing strains were compared using χ 2 , Fisher exact, and Student t test analyses, as appropriate.
RESULTS

Clinical Results
Eighty-two laboratory-proved pertussis cases were identified during the 7-year study period. Ten cases were excluded (2 PCR positive only, 8 direct fluorescent antibody positive only) because culture was not performed or had negative results. Of the 72 culture-positive cases, 12 cases were excluded owing to nonviability of frozen organisms. The final study population of 60 cases represented 73.2% of cases confirmed during the study period. Excluded cases were from all study years. The 12 cases excluded due to nonviable organisms had similar demographic and clinical characteristics to the study cohort, with the exception of mortality-the only 2 patients with pulmonary hypertension and death (study years 2010 and 2012) had nonviable isolates. All patients' medical records were available for review. Overall, 68.3% (n = 41) of the study population had infection with pertactin-deficient B. pertussis strains. The first pertactindeficient strain was isolated in 2008, and these strains generally increased during the study years ( Figure 1 ). The majority of cases due to pertactin-deficient strains occurred in 2011 and 2012 (n = 32), accounting for 78% of all cases of pertactindeficient strains. No laboratory-confirmed case of pertussis was identified in 2013.
Demographic and clinical characteristics of the study population, with comparison of B. pertussis pertactin-producing and pertactin-deficient cases, are shown in Table 1 . The median age of the cohort was 95 days; 66.7% of patients were <4 months of age. Less than 15% of the cohort had an identifiable underlying condition, and no patient had congenital cardiac disease, neuromuscular disease, immunodeficiency, or malignancy. The average length of illness before presentation was shorter for the pertactin-deficient group (mean difference, 3.2 days; P = .04). There were no statistically significant differences in presenting symptoms or signs relative to pertactin expression. However, infants infected with pertactin-deficient strains had posttussive emesis, apnea, and choking or gagging reported less often but cyanosis reported more often. In cases due to pertactinproducing B. pertussis, there was a trend to report a first-degree relative contact with illness (P = .09). Documented vaccination status was age appropriate in 80% of the cohort (delayed in 8% and unknown in 12%); however, owing to their young age, 90% of the 52 patients with known vaccination history had received no dose or just 1 dose of DTaP. No mother had received Tdap during pregnancy.
Forty-three patients (72% of cohort) were hospitalized, and the majority of these patients (n = 27) had infection with pertactin-deficient strains. Rates of hospitalization ranged from 60% to 90% annually and did not differ between cases caused by pertactin-deficient and those caused by pertactin-producing B. pertussis. The median length of hospital stay and severity of clinical course were similar between groups. Overall, 15% of the study cohort was admitted to the intensive care unit, and 20% of those patients required respiratory support; there were no apparent differences between patients with pertactin-deficient and pertactin-producing B. pertussis. One-half of study patients had ≥1 complete blood cell count performed, with median white blood cell (WBC) counts demonstrating lymphocytosis (median WBC count, 17 000/μL; 69% lymphocytes). Initial laboratory test results for cases due to pertactin-producing and pertactin-deficient strains were similar (median WBC count, 16 000/μL vs 17 900/μL, respectively; lymphocyte proportion, 72.5% vs 70%; absolute lymphocyte count, 10 850/μL vs 9834/μL; and platelet count, 408 000/μL vs 373 000/μL; all P > .05).
Clinical Subgroup Analysis Results
Infants <4 months of age (n = 40) were considered separately because they represent a subgroup at heightened risk of severe disease. Thirty-six of 43 hospitalized cases (84%) occurred in infants <4 months of age. The proportion of pertactin-deficient and pertactin-producing cases was similar to that of all hospitalized patients. Among these young infants, there were no apparent clinical differences between cases due to pertactindeficient and pertactin-producing B. pertussis: days of illness before presentation, presenting signs and symptoms, identification of likely source contacts, disease severity, or level of hospital care (data not shown; all P > .05).
Molecular Results
Sequencing of the entire pertactin-encoding region revealed that all but 1 isolate carried the prn2 allele. A single isolate from 2009 carried the prn1 allele. A total of 41 (68%) of 60 isolates had no pertactin protein identifiable by Western blot; all had prn mutations delineated. The 19 isolates with pertactin expression had no prn mutation detected. Figure 2 highlights the molecular characteristics of the cohort by year and PFGE type. Eleven PFGE profiles were identified among the 60 isolates, of which 5 correlated with published PFGE types (CDC 002, 010, 013, 237, and 334). CDC 002 and CDC 013 were present throughout the study period, with the predominant CDC 002 type accounting for 47% of the study cohort overall. CDC 002 seems to have shifted to a pertactin-deficient state in 2009, with no pertactin-producing isolate of CDC 002 strain since 2010. CDC 013 isolates remained pertactin-producing until 2012. CDC 334 and CDC 237 types emerged in 2011 as predominantly pertactin-deficient variants (12 of 14; 85%).
The 19 pertactin-producing isolates belonged to 9 PFGE types and the 41 pertactin-deficient isolates belonged to 5 PFGE types. Four PFGE types had both pertactin-deficient and pertactin-producing isolates. Of the 41 pertactin-deficient isolates, pertactin whole-gene sequencing identified both insertion sequence (IS481) and stop codon disruptions as mutation mechanisms for pertactin deficiency. In addition, stop codons were identified at 2 locations (stop 760 and 1273), whereas IS481 was noted at 3 nucleotide locations (245, 1613, and 2728) within the prn gene. Mutation mechanisms and nucleotide positions were not unique to PFGE type, nor were they clustered in time (Figure 2) . Stop codon at position 1273 was the most common mutation, found in 23 isolates among 2 PFGE types, followed by IS481 at 1613 in 10 isolates among 3 PFGE types (Figure 2 ).
DISCUSSION
Our findings in this group of predominantly unimmunized infants suggest that deficiency of pertactin expression does not alter disease manifestations. These findings generally are in agreement with those of Bodilis and Guiso [23] , who compared B. pertussis pertactin expression with clinical pertussis presentation in infants <6 months of age in France, through questionnaires sent to the infants' pediatricians. They found only a significantly longer time from onset of signs and symptoms to sample collection in patients with pertactin-deficient compared with pertactin-producing isolates (mean, 14.6 vs 9.9 days; P = .04). Our cases with pertactin-deficient strains had a significantly shorter time from onset of illness to presentation compared with pertactin-producing cases (mean. 6.4 vs 9.6 days, respectively; P = .04). However, within the subgroup <4 months of age, no difference was found. No other clinical manifestation with statistically significant difference was found between cases due to pertactin-deficient and those due to pertactin-producing B. pertussis in our study, regardless of age.
The only other study reporting demographic and clinical characteristics by pertactin expression comprised predominantly older, immunized individuals [1] . In data collected from public health records of 753 cases from 8 states in the United States during 2011-2013, the only clinical difference between cases with pertactin-deficient and those with pertactin-producing isolates was apnea, which was reported in 23% of cases due to pertactin-deficient versus 37% due to pertactin-producing strains (P = .05). It is difficult to assess meaningfulness of "apnea" differences when the wide variability in rates of occurrence across studies suggests possible dissimilar use of the term by age, geography and culture. Apnea was reported in cases of pertactindeficient versus pertactin-producing isolates, respectively, in 12.2% versus 15.8% by medical record review in our study, 62% versus 46% by pediatrician questionnaire in Paris, and 23% versus 37% by public health reporting from 8 US states [1, 23] .
Retained virulence of B. pertussis lacking pertactin also has been demonstrated in mouse [27] and primate models (Tod J. Merkel, personal written communication, 9 April 2015). In fact, Hegerle and Guiso [28] concluded that reduced cell cytotoxicity was observed among pertactin-deficient isolates when coincubated with specific anti-pertactin antibodies, suggesting that the absence of pertactin, compared with its presence, may provide a selective advantage for more sustained infection after acellular pertussis immunization [29] .
B. pertussis is a highly contagious mucosal infection for which neither disease nor vaccination provides prolonged immunity to disease or protection from colonization. These circumstances foster adaptation under selective pressure with continuous evolution of "escape mutants." After universal use of whole-cell pertussis vaccine, antigenic divergence of circulating strains from vaccine strains was found in the United States and worldwide [13, 14] . Changes in predominant ptx, prn, and fim alleles were the first divergences from vaccine antigens, followed by change in the toxin promotor gene, ptxP [12, 13] . Only the change in promotor gene, which up-regulated pertussis toxin expression, was consistently associated with increased notifications of pertussis in Europe. The recent and sustained appearance of multiclonal pertactin-deficient B. pertussis is a phenomenon associated with use of acellular pertussis vaccines in the United States and other countries and has not occurred in countries such as Poland and Serbia, where whole-cell vaccines continue to be used [14] .
The first pertactin-deficient strain of B. pertussis in our cohort was isolated in 2008, with increasing prevalence in subsequent years and overall prevalence of 68% for the study period. Screening of 1300 US clinical isolates from national outbreak and surveillance collections from 1935 to 2009 found that the first pertactin-deficient strain was isolated in 1994, and the second only in 2010 (during a California outbreak). Since 2010, pertactin-deficient strains have increased dramatically both in state outbreaks (eg, Washington state in 2012) [15] , and nationally to a prevalence of just over 50% in 2012 [30] . The rapid rise of mutant strains in our Philadelphia study and in national surveillance studies in the United States [30] and Australia [19] all share the common feature of occurrence only during exclusive use of acellular pertussis vaccines.
Our relatively small collection of 41 pertactin-deficient isolates since 2008 shows remarkable strain diversity of PFGE types as well as multiple mechanisms and molecular sites of pertactin inactivation. These data suggest that pertactindeficient B. pertussis arose as multiple genetic events, rather than by clonal expansion of a single or few mutants. Such diversity also has been shown among larger collections of isolates studied from endemic and outbreak settings in the United States [30] and Australia [19] .
Host production of anti-pertactin antibody is singularly crucial for enhanced phagocytosis of pertactin-producing B. pertussis [31] . In vaccine efficacy trials, acellular pertussis vaccines containing pertactin were superior to acellular pertussis vaccines consisting only of pertussis toxoid and filamentous hemagglutinin [32, 33] . However, in a 2015 retrospective US study, Martin et al [1] noted that patients who had received ≥1 pertussis vaccine dose had an adjusted odds ratio of 2.2 (95% confidence interval, 1.3-4.0) for having a pertactin-deficient isolate, suggesting possible bacterial selective advantage. Mooi et al [34] and Clark [2] proposed integrated explanations for the shortfall of current acellular vaccines, which include contributions from host and pathogen. The diminished type 1 helper T-lymphocyte response after acellular vaccines, compared with a mixed types 1 and 2 helper T-lymphocyte response after wholecell vaccines, probably leads to a robust but narrow range of antibodies with little cell-mediated immunity and uniquely increased susceptibility to infection as antibodies wane after DTaP and Tdap [22, [35] [36] [37] [38] . Continuous allelic adaptation of B. pertussis and this most recent loss of pertactin as a major vaccine target may each play a role.
The current study demonstrates the importance of obtaining culture isolates from patients even when molecular identification augments diagnosis. Sequencing of the entire pertactin coding region, rather than targeted search for known mutations in the prn gene, was essential to discovery of the mutant strains. Our study has substantial strengths, including collection of isolates over years that represent 73% of diagnosed cases in a young predominantly unvaccinated cohort, and use of sequencing of the pertactin gene to identify mutations leading to deficiency. Study limitations include its retrospective design, the nonviability of some isolates, including those from our only fatal cases during the study period, and the small number of cases. None of the 2014 mothers in our study received Tdap vaccine during pregnancy, probably owing to the relative newness of the 2013 Tdap recommendations for pregnant women in the United States. Our findings of high prevalence of and full disease manifestations for pertactin-deficient B. pertussis in young infants underscore the urgency for implementation of the current recommendation for immunization in latter pregnancy to provide high levels of vaccine-induced antibody transplacentally, especially against pertussis toxin, to protect against disease through the highly vulnerable first months of life.
